Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Apoptotic Killing of Breast Cancer Cells by IgYs Produced Against a Small 21 Aminoacid Epitope of the Human TRAIL-2 Receptor

  • Amirijavid, Shaghayegh (Department of Genetics, Tehran Medical Sciences Branch, Islamic Azad University) ;
  • Entezari, Maliheh (Department of Genetics, Tehran Medical Sciences Branch, Islamic Azad University) ;
  • Movafagh, Abolfazl (Department of Medical genetics, School of Medicine, Shahid Beheshti University of Medical Sciences) ;
  • Hashemi, Mehrdad (Department of Genetics, Tehran Medical Sciences Branch, Islamic Azad University) ;
  • Mosavi-Jarahi, Alireza (Department of Medical Laboratory Sciences, Tehran Medical Sciences Branch, Islamic Azad University) ;
  • Dehghani, Hossein (Department of Epidemiology, Shahid Beheshti University of Medical Sciences)
  • Published : 2016.06.01
Download PDF
⟨ Previous Next ⟩

Abstract

TRAIL, tumor necrosis factor (TNF)-related apoptosis-inducing ligand belongs to one of important cytokine superfamilIES, tumor necrosis factor ($TNF{\alpha}$). TRAIL-2 receptor agonists activate several cell signaling pathways in cells in different manners and could lead to apoptosis or necrosis. Agonistic egg yolk antibodies like IgY which have been developed in a selective manner could activate TRAIL death receptors such as TRAIL-2 (DR5) and thus apoptosis signaling. We here investigated induction of apoptosis in human breast cancer cells (MCF7 cell line) by an IgY produced against an 21 aminoacid epitope of the human TRAIL-2 receptor. As the first step a small peptide of 21 aminoacids choosen from the extracellular domain of DR5 protein was produced with a peptide synthesizer. After control assays and confirmation of the correct amino acid sequence, it was injected to hens immunized to achieve high affinity IgYs. At the next step, the produced IgYs were extracted and examined for specificity against DR5 protein by ELISA assay. Subsequently, the anticancer effect of such IgYs was determined by MTT assay in the MCF7 human breast cancer cell line. The produced peptides successfully immunized hens and the produced antibodies which accumulated in egg yolk specifically recognized the DR5 protein. IgYs exerted significant toxicity and killed MCF7 cells as shown by MTT assay.

Keywords

References

  1. Amaral JA, De-Franco MT, Carneiro-Sampaio MMS, et al. (2002). Antienteropathogenic Escherichia coli immunoglobulin Y isolated from eggs laid by immunized Leghorn chickens. Res Vet Sci, 72, 229-34. https://doi.org/10.1053/rvsc.2002.0551
  2. Almasan A, Ashkenazi A (2003). po2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev, 14, 337-48. https://doi.org/10.1016/S1359-6101(03)00029-7
  3. Almeida CMC, Kanashiro MM, Filho FBR, et al. (1998). Development of snake antivenom antibodies in chickens and their purification from yolk. Vet Rec, 143, 579-84. https://doi.org/10.1136/vr.143.21.579
  4. Ashkenazi A, Dixit VM. (1999). Apoptosis control by death and decoy receptors. Curr Opin Chem Biol, 11, 255-60. https://doi.org/10.1016/S0955-0674(99)80034-9
  5. Ashkenazi A. (2008). Targeting the extrinisic apoptosis pathway in cancer cytokine growth factor. Cytokine Growth Factor Rev, 19, 325-31. https://doi.org/10.1016/j.cytogfr.2008.04.001
  6. Bodmer JL, Holler N, Reynard S, et al. (2000). Trail receptor-2 signals apoptosis through FADD and caspase-8. J Nat Cell Biol, 2, 241-3. https://doi.org/10.1038/35008667
  7. Bollen LS, Hau J (1996). Chicken eggs in polyclonal antibody production. Scand J Lab Anim Sci, 23, 85-91.
  8. Chalghoumi R, Beckers Y, Portetelle D, et al. (2009). Hen egg yolk antibodies (IgY), production and use for passive immunization against bacterial enteric infections in chicken: a review. Biotechnol Agron Soc Environ, 13, 295-308.
  9. Chen KF, Chen HL, Liu CY, et al (2012). Dovitinib sencitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3. Biochem Pharmacol, 83, 769-77. https://doi.org/10.1016/j.bcp.2011.12.035
  10. Dias da Silva W, Tambourgi DV (2010). IgY: A promising antibody for use in immunodiagnostic and in immunotherapy. Vet Immunol Immunopathol, 135, 173-80. https://doi.org/10.1016/j.vetimm.2009.12.011
  11. Di-Lonardo M, Marcante L, Poggiali F, et al (2001). Egg yolk antibodies against the E7 oncogenic protein of human papillomavirus type 16. Arch Virol, 146, 117-25. https://doi.org/10.1007/s007050170195
  12. Du YW, Chen JG, Bai HL, et al (2011). A novel agonistic anti-human death receptor 5 monoclonal antibody with tumoricidal activity induces caspase- and mitochondrial-dependent apoptosis in human leukemia Jurkat cells. Cancer Biother Radiopharm, 26, 143-52. https://doi.org/10.1089/cbr.2010.0827
  13. Guo Y, Chen C, Zheng Y, et al (2005). A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent Cell Death Dis, 280, 41940-52.
  14. Hau J, Westergaard JG, Svendsen P, et al (1980). Comparison between pregnancy-associated murine protein-2 (PAMP-2) and human pregnancy specific beta-1-glycoprotein (SP-1). J Reprod Fertil, 60, 115-9. https://doi.org/10.1530/jrf.0.0600115
  15. Hau J, Westergaard JG, Svendsen P, et al (1981). Comparison of pregnancy-associated protein-1 and human pregnancy zone protein. J Reprod Immunol, 3, 341-9. https://doi.org/10.1016/0165-0378(81)90050-4
  16. Ichikawa K, Liu W, Zhao L, et al (2010). Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med, 7, 954-60.
  17. Jo M, Kim TH, Seol DW, et al (2000). Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med, 6, 564-67. https://doi.org/10.1038/75045
  18. Kelley RF, Totpal K, Lindstrom SH, et al (2005). Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem, 280, 2205-12. https://doi.org/10.1074/jbc.M410660200
  19. Kimberley FC, Screaton GR (2004). Following a TRAIL: update on a ligand and its five receptors. Cell Res, 14, 359-72. https://doi.org/10.1038/sj.cr.7290236
  20. Kischkel FC, Lawrence DA, Chuntharapai A, et al (2000). Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity, 12, 611-20. https://doi.org/10.1016/S1074-7613(00)80212-5
  21. Lawrence D, Shahrokh Z, Marsters S, et al. (2001). Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med, 7, 383-5. https://doi.org/10.1038/86397
  22. Lebedeva IV, Su ZZ, Sarkar D, et al (2003). Restoring apoptosis as a strategy for cancer gene therapy: focus on p53 and mda-7. Sem Cancer Biol, 13, 169-78. https://doi.org/10.1016/S1044-579X(02)00134-7
  23. LeBlanc HN, Ashkenazi A (2003). Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ, 10, 66-75. https://doi.org/10.1038/sj.cdd.4401187
  24. Lemamy GJ, Roger P, Mani JC, et al. (1999). Highaffinity antibodies from hen's-egg yolk against human mannose-6 phosphate/insulin-like growth-factor-II receptor (MGP/IGFII-R): Characterization and potential use in clinical cancer studies. Int J Cancer, 80, 896-902. https://doi.org/10.1002/(SICI)1097-0215(19990315)80:6<896::AID-IJC16>3.0.CO;2-J
  25. Leslie GA, Clem LW (1969). Phylogeny of immunoglobulin structure and functions. III. Immunoglobulins of the chicken. J Exp Med, 130, 1337-52. https://doi.org/10.1084/jem.130.6.1337
  26. Ozoren N, Kim K, Burns TF, et al (2000). The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res, 60, 6259-65.
  27. Salcedo TW, Alderson RF, Basu S, et al (2002). TRM-1, a fully human TRAIL-R1 agonistic monoclonal antibody, displays in vitro and in vivo anti-tumor activity. Proc Annu Meet Am Assoc Cancer Res, 43, 856.
  28. Sarker SA, Casswall TH, Juneja FL, et al (2001). Randomised, placebo-controlled, clinical trial of hyperimmunised chicken egg yolk immunoglobulin (HEY) in children with rotavirus diarrhoea. J Pediat Gastroenterol Nutr, 32, 19-25. https://doi.org/10.1097/00005176-200101000-00009
  29. Schade R, Hlinak A, Marburger A, et al (1997). Advantages of using egg yolk antibodies in the life sciences: the results of five studies. ATLA-Altern Lab Anim, 25, 555-86.
  30. Shargh SA, Sakizli M, Khalaj V, et al (2014). Downregulation of E-cadherin expression in breast cancer by promoter hypermethylation and its relation with progression and prognosis of tumor. Med Oncol, 31, 250. https://doi.org/10.1007/s12032-014-0250-y
  31. Sprick MR, Weigand MA, Rieser E, et al (2000). FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity, 12, 599-609. https://doi.org/10.1016/S1074-7613(00)80211-3
  32. Svendsen L, O'Brien D, Stodulski G, et al (1994). Use of chickens and exploitation of egg yolk antibody production. In: Welfare and Science (Bunyan J ed). Royal Society of Medicine Press, London, 324-7.
  33. Thompson CB. (1995). Apoptosis in the pathogenesis and treatment of disease. Science, 267, 1456-62. https://doi.org/10.1126/science.7878464
  34. Tini M, Jewell UR, Camenish G. (2002). Generation and application of chicken egg-yolk antibodies. Comp Biochem Physiol, 131, 569-74. https://doi.org/10.1016/S1095-6433(01)00508-6
  35. Walczak H, Miller RE, Ariail K, et al (1999). Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med, 5, 157-63. https://doi.org/10.1038/5517
  36. Xiang H, Reyes AE, Eppler S, et al (2013). Death receptor 5 agonistic antibody PRO 95780: preclinical pharmacokinetics and concentration-effect relationship support clinical dose and regimen selection. Cancer Chemother Pharmacol, 75, 1-11.